Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Halozyme Therapeutics Inc shares valued at $271,467 were sold by Henderson Jeffrey William on Apr 28 ’25. At $60.37 per share, Henderson Jeffrey William sold 4,497 shares. The insider’s holdings dropped to 28,611 shares worth approximately $1.56 million following the completion of this transaction.
Also, Henderson Jeffrey William sold 503 shares, netting a total of over 32,217 in proceeds. Following the sale of shares at $64.05 each, the insider now holds 33,108 shares.
Before that, Henderson Jeffrey William had sold 5,000 shares from its account. In a trade valued at $293,458, the Director traded Halozyme Therapeutics Inc shares for $58.69 each. Upon closing the transaction, the insider’s holdings decreased to 5,000 shares, worth approximately $1.83 million.
As published in a research note from Morgan Stanley on May 14, 2025, Halozyme Therapeutics Inc [HALO] has been rated down from an Overweight to an Equal-weight and the price target has been revised to $62. Analysts at Leerink Partners downgraded the stock from ‘”a Market perform”‘ to ‘”an Underperform”‘ outlook in a report released in mid May. As of October 07, 2024, Wells Fargo has decreased its “an Overweight” rating to a “an Equal weight” for HALO. Earlier on September 19, 2024, JP Morgan downgraded its rating. Their new recommendation was “a Neutral” for HALO stock which previously was a “an Overweight”.
Analyzing HALO Stock Performance
On last trading session,, Halozyme Therapeutics Inc [NASDAQ: HALO] rose 1.28% to $54.54. The stock’s lowest price that day was $53.65, but it reached a high of $54.54 in the same session. During the last five days, there has been a surge of approximately 1.85%. Over the course of the year, Halozyme Therapeutics Inc shares have jumped approximately 14.08%.
Support And Resistance Levels for Halozyme Therapeutics Inc (HALO)
RSI (Relative Strength Index) is 46.78 on the 14-day chart, showing neutral technical sentiment.
Is Halozyme Therapeutics Inc subject to short interest?
Stocks of Halozyme Therapeutics Inc saw a sharp rise in short interest on 2025-05-30 jumping by 1.09 million shares to 10.55 million. Data from Yahoo Finance shows that the short interest on 2025-04-30 was 9.46 million shares. A jump of 10.33% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 3.21 of the overall float, the days-to-cover ratio (short ratio) jumped to 3.21.
Which companies own the most shares of Halozyme Therapeutics Inc (HALO)?
In terms of Halozyme Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 62 in the next 12 months, up nearly 15.13% from the previous closing price of $53.85. Analysts anticipate Halozyme Therapeutics Inc stock to reach 62 by 2025, with the lowest price target being 62. In spite of this, 7 analysts ranked Halozyme Therapeutics Inc stock as Buy at the end of 2025. On June 07, 2024, Piper Sandler assigned a price target of “a Neutral” to the stock and downgraded coverage with a $51.
